Rheumatologists collect 73.7% of their total Medicare Part B revenue from drug and biological injections — more than any other physician specialty, and nearly 15 percentage points above hematology-oncology. That number reframes what a rheumatology practice actually is: less a diagnostic service, more a drug-delivery operation.

Key Numbers

• $10.6 billion — Medicare Part B drug and biological payments in 2022, up from $5.9 billion in 2013, a 81% increase over the decade
• 7.62% to 11.93% — drug spending's share of total Part B payments, 2013 to 2022
• $20.5 billion — total Medicare payments for aflibercept (J0178) across all years, the single most expensive drug code by a wide margin
• 73.7% — share of rheumatology's total Medicare revenue coming from drug/biological codes, the highest of any clinical specialty
• $2,928 — average Medicare payment per service for pegfilgrastim (J2505), the highest per-service rate among the top-spending drug codes

---

Drug Spending's Share of Part B Has Nearly Doubled Since 2013

In 2013, drug and biological codes accounted for 7.62% of total Medicare Part B payments. By 2022, that share had reached 11.93%. The climb was nearly uninterrupted — the only exception was 2020, when non-drug service volume collapsed (total non-drug payments dropped from $79.4 billion in 2019 to $70.5 billion in 2020) while drug spending held relatively steady at $10.0 billion, briefly pushing the drug share to a peak of 12.43%.

The number of unique drug HCPCS codes billed also grew, from 361 in 2013 to 388 in 2022. Non-drug service codes expanded too, from 5,622 to 5,938, but the drug category's payment growth outpaced its code count growth by a wide margin. Fewer codes, more dollars.

---

One Eye Drug Dominates the Entire Medicare Drug Budget

Aflibercept (J0178), an injection used to treat macular degeneration and diabetic retinopathy, generated $20.5 billion in total Medicare payments across 11 years — more than 2.6 times the second-ranked drug, ranibizumab (J2778) at $7.8 billion. Both treat the same conditions. Both are administered by ophthalmologists.

Ophthalmology as a specialty collected $72.1 billion in total Medicare Part B payments across the dataset — the largest absolute total of any specialty shown — with 43.6% coming from drug codes. The two retinal injection drugs alone account for a combined $28.3 billion, which exceeds the entire drug spend of the rheumatology specialty ($12.8 billion) by more than double.

Pegfilgrastim (J2505), a white blood cell stimulator used after chemotherapy, sits at the opposite end of the volume spectrum: only 1.1 million total services billed, but an average payment of $2,928 per service — the highest per-service rate in the top-20 drug codes. Denosumab (J0897), by contrast, generated $6.2 billion from 429 million services at just $14.26 each. Same drug category, radically different billing structures.

---

Rheumatology and Oncology Are Effectively Drug-Delivery Specialties

The specialty breakdown reveals a structural divide in how Medicare Part B money flows. Rheumatology leads all clinical specialties with 73.7% of its $17.4 billion in total payments coming from drug and biological codes. Hematology-oncology follows at 59.6% of $22.7 billion, and medical oncology at 58.7% of $9.3 billion.

Neurology sits at the other extreme: 16.2% drug share on $13.6 billion in total payments. Neurologists bill 197 unique drug codes — nearly as many as hematology-oncology's 279 — but the payment weight stays firmly on the service side. Allergy/immunology lands at 32.3% drug share, despite billing 120 unique drug codes across 4,215 providers.

Mass immunization roster billers — entities that exist primarily to administer vaccines — clock in at 61.8% drug share, but their 19 unique drug codes tell the story: this is a narrow, high-volume operation, not a broad therapeutic portfolio.

---

Open Questions

1. Aflibercept and ranibizumab treat the same retinal conditions, yet aflibercept generated 2.6 times more total Medicare spending — does the payment differential per service ($740 vs. $273) explain the volume shift, or did prescribing patterns drive it independently?

2. Drug spending's share of Part B payments peaked at 12.43% in 2020 when non-drug service volume collapsed — how much of the post-2020 share decline (back to 11.93% by 2022) reflects a genuine rebalancing versus a mechanical recovery in procedure volume?

3. Rheumatology's 73.7% drug revenue share comes from 6,621 providers billing 198 unique drug codes — how concentrated is that spending across individual drugs, and does a handful of biologics like abatacept and infliximab account for the bulk of it?